One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats
Authors:
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Radius Health, Inc
This publication has 26 references indexed in Scilit:
- Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fracturesJournal of Bone and Mineral Research, 2011
- RANKL Inhibition with Osteoprotegerin Increases Bone Strength by Improving Cortical and Trabecular bone Architecture in Ovariectomized RatsJournal of Bone and Mineral Research, 2008
- Interrelationships Between Bone Microarchitecture and Strength in Ovariectomized Monkeys Treated With TeriparatideJournal of Bone and Mineral Research, 2007
- A biomechanical perspective on bone qualityBone, 2006
- Effects of Cyclic Versus Daily hPTH(1-34) Regimens on Bone Strength in Association With BMD, Biochemical Markers, and Bone Structure in MiceJournal of Bone and Mineral Research, 2006
- Six-Month Daily Administration of Parathyroid Hormone and Parathyroid Hormone—Related Protein Peptides to Adult Ovariectomized Rats Markedly Enhances Bone Mass and Biomechanical Properties: A Comparison of Human Parathyroid Hormone 1–34, Parathyroid Hormone-Related Protein 1–36, and SDZ-Parathyroid Hormone 893Journal of Bone and Mineral Research, 2000
- Distal radius fractures: Mechanisms of injury and strength prediction by bone mineral assessmentJournal of Orthopaedic Research, 1998
- Parathyroid hormone (1–34) increases vertebral bone mass, compressive strength, and quality in old ratsBone, 1995
- Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. A one-year study.Journal of Clinical Investigation, 1995
- Marked decrease in trabecular bone quality after five years of sodium fluoride therapy; assessed by biomechanical testing of iliac crest bone biopsies in osteoporotic patientsBone, 1994